Joseph Helft, MD
Cardiovascular Disease · Bronx, NYNPI 1659478477
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $457,179 of the $488,081 with a category attached, or 93.7%. 36 manufacturers reported payments, led by Novo Nordisk at 38.3% of the total. Reporting peaked in 2019 at $143,366 and has fallen 98.4% since, to $2,257 in 2025. Among cardiovascular disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,059 payments — averaging $460.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$187K
- Johnson & Johnson$146K
- Amgen$46K
- Boehringer Ingelheim$45K
- Pfizer$25K
- E.r. Squibb & Sons, L.L.C.$22K
- plus $18K from 30 others
What the payments were for
- Consulting fees$2,3550%
- Speaking & faculty fees$457,17994%
- Travel & lodging$4,7711%
- Food & beverage$23,7325%
- Education$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 147 | $186,917 |
| Johnson & Johnson | 189 | $145,796 |
| Amgen | 115 | $45,630 |
| Boehringer Ingelheim | 79 | $45,227 |
| Pfizer | 78 | $24,602 |
| E.r. Squibb & Sons, L.L.C. | 59 | $22,024 |
| Abbott | 15 | $6,140 |
| Lilly USA, LLC | 9 | $4,652 |
| AstraZeneca | 71 | $1,380 |
| Novartis | 62 | $857 |
| Merck | 31 | $664 |
| Boston Scientific | 27 | $552 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $500 |
| Edwards Lifesciences | 18 | $438 |
| Sanofi-aventis U.S. LLC | 22 | $422 |
| Lexicon Pharmaceuticals, Inc. | 29 | $369 |
| Esperion Therapeutics, Inc. | 24 | $330 |
| Bayer | 15 | $252 |
| Amarin Pharma, Inc. | 15 | $246 |
| Scpharmaceuticals Inc. | 8 | $195 |
| Kowa Pharmaceuticals America, Inc. | 13 | $192 |
| Alnylam Pharmaceuticals Inc. | 6 | $128 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $104 |
| Shockwave Medical, Inc | 1 | $97 |
| Bristol Myers Squibb | 4 | $76 |
| Arbor Pharmaceuticals, Inc. | 3 | $48 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $46 |
| Regeneron Healthcare Solutions, Inc. | 2 | $42 |
| Gilead | 2 | $30 |
| Medtronic | 2 | $29 |
| Bridgebio Pharma, Inc. | 1 | $20 |
| Amryt Pharma Holdings Ltd | 1 | $19 |
| Heartflow, Inc. | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $16 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $15 |
| Portola Pharmaceuticals, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$488,081 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 327 | $348,480 |
| EntrestoSacubitril/Valsartan | 163 | $194,507 |
| XareltoRivaroxaban | 141 | $138,392 |
| JardianceEmpagliflozin | 53 | $55,603 |
| Repatha SureclickEvolocumab | 63 | $49,045 |
| MultaqDronedarone Hcl | 26 | $48,525 |
| OzempicSemaglutide | 38 | $34,866 |
| BrilintaTicagrelor | 21 | $22,274 |
| Praluent PenAlirocumab | 32 | $19,913 |
| MounjaroTirzepatide | 14 | $14,673 |
| JanuviaSitagliptin Phosphate | 13 | $11,342 |
| Metoprolol Succinate | 566 | $8,792 |
| Rosuvastatin Calcium | 364 | $4,909 |
| Ranolazine ErRanolazine | 48 | $4,443 |
| Digoxin | 40 | $3,350 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $24,602 | $348,480327 claims |
| NovartisEntresto | $857 | $194,507163 claims |
| Johnson & JohnsonXarelto | $145,796 | $138,392141 claims |
| Boehringer IngelheimJardiance | $45,227 | $55,60353 claims |
| Sanofi-aventis U.S. LLCMultaq | $422 | $48,52526 claims |
| Novo NordiskOzempic | $186,917 | $34,86638 claims |
| AstraZenecaBrilinta | $1,380 | $22,27421 claims |
| Lilly USA, LLCMounjaro | $4,652 | $14,67314 claims |
| MerckJanuvia | $664 | $11,34213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Bronx
- Luigi di BiaseBronx$978K
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Augustin DelagoAlbany$1.8M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Vijay IyerAmherst$855K
- Megha PrasadNew York$813K
- Ronald DagostinoLake Success$782K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.